CRGD Peptide-conjugated Polyethylenimine-based Lipid Nanoparticle for Intracellular Delivery of SiRNA in Hepatocarcinoma Therapy

Overview

Journal Drug Deliv

Specialty Pharmacology

Date 2021 May 27

PMID 34042551

Citations 7

Authors

Shuang Yang

Dandan Wang

Xia Zhang

Yaojun Sun

Bin Zheng

Affiliations

Soon will be listed here.

Abstract

The effective delivery system plays an important role in the application of siRNA in the antitumor study. However, until now, researches on the delivery systems targeting hepatocarcinoma cells are still being explored. Here we designed and prepared a novel siRNA delivery system, cRGD-PSH-NP, which was based on a modified polyethyleneimine (PSH) and DSPE-PEG-cRGD. cRGD-PSH-NP loaded with survivin siRNA (cRGD-PSH-NP/S) was composed of egg phosphatidylcholine, cationic PSH, PEGylated lipids, survivin siRNA, and cRGD peptide as a targeting ligand. The formulations of cRGD-PSH-NP/S were optimized and characterized. investigations showed excellent gene silencing and antitumor activity compared with the unmodified nanoparticles in HepG2 cells. antitumor efficacy of cRGD-PSH-NP/S exhibited potent tumor inhibition (74.71%) in HepG2-bearing nude mice without inducing toxicity. These data suggested further research of cRGD-PSH-NP/S in hepatocarcinoma therapy.

Citing Articles

The Role of Small Interfering RNAs in Hepatocellular Carcinoma.

Chen F, Zhang W, Gao X, Yuan H, Liu K J Gastrointest Cancer. 2023; 55(1):26-40.

PMID: 37432548 DOI: 10.1007/s12029-023-00911-w.

The use of RNA-based treatments in the field of cancer immunotherapy.

Chehelgerdi M, Chehelgerdi M Mol Cancer. 2023; 22(1):106.

PMID: 37420174 PMC: 10401791. DOI: 10.1186/s12943-023-01807-w.

Ferric-loaded lipid nanoparticles inducing ferroptosis-like cell death for antibacterial wound healing.

Zhou Y, Cai C, Wang C, Hu G, Li Y, Han M Drug Deliv. 2022; 30(1):1-8.

PMID: 36453025 PMC: 9721425. DOI: 10.1080/10717544.2022.2152134.

Pheophorbide A-Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression.

Tong Q, Xu J, Wu A, Zhang C, Yang A, Zhang S Pharmaceutics. 2022; 14(11).

PMID: 36432703 PMC: 9697200. DOI: 10.3390/pharmaceutics14112513.

Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy.

Foglizzo V, Marchio S Cancers (Basel). 2022; 14(10).

PMID: 35626078 PMC: 9139219. DOI: 10.3390/cancers14102473.

References

Khalil I, Yamada Y, Harashima H . Optimization of siRNA delivery to target sites: issues and future directions. Expert Opin Drug Deliv. 2018; 15(11):1053-1065. DOI: 10.1080/17425247.2018.1520836. View

Barba A, Bochicchio S, Dalmoro A, Lamberti G . Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications. Pharmaceutics. 2019; 11(8). PMC: 6723796. DOI: 10.3390/pharmaceutics11080360. View

Mainini F, Eccles M . Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy. Molecules. 2020; 25(11). PMC: 7321291. DOI: 10.3390/molecules25112692. View

Jiang Y, Hardie J, Liu Y, Ray M, Luo X, Das R . Nanocapsule-mediated cytosolic siRNA delivery for anti-inflammatory treatment. J Control Release. 2018; 283:235-240. PMC: 6054481. DOI: 10.1016/j.jconrel.2018.06.001. View

Subhan M, Torchilin V . Efficient nanocarriers of siRNA therapeutics for cancer treatment. Transl Res. 2019; 214:62-91. DOI: 10.1016/j.trsl.2019.07.006. View

Dong Y, Siegwart D, Anderson D . Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019; 144:133-147. PMC: 6745264. DOI: 10.1016/j.addr.2019.05.004. View

Setten R, Rossi J, Han S . The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019; 18(6):421-446. DOI: 10.1038/s41573-019-0017-4. View

Khan A, Alanazi A, Jabeen M, Chauhan A, Ansari M . Therapeutic potential of functionalized siRNA nanoparticles on regression of liver cancer in experimental mice. Sci Rep. 2019; 9(1):15825. PMC: 6825139. DOI: 10.1038/s41598-019-52142-4. View

Tang X, Zhou S, Tao X, Wang J, Wang F, Liang Y . Targeted delivery of docetaxel via Pi-Pi stacking stabilized dendritic polymeric micelles for enhanced therapy of liver cancer. Mater Sci Eng C Mater Biol Appl. 2017; 75:1042-1048. DOI: 10.1016/j.msec.2017.02.098. View

10.

Yang S, Lee R, Yang X, Zheng B, Xie J, Meng L . A novel reduction-sensitive modified polyethylenimine oligonucleotide vector. Int J Pharm. 2015; 484(1-2):44-50. DOI: 10.1016/j.ijpharm.2015.02.036. View

11.

Zheng B, Yang S, Tian Q, Xie Y, Zhang S, Lee R . Delivery of Antisense Oligonucleotide LOR-2501 Using Transferrin-conjugated Polyethylenimine-based Lipid Nanoparticle. Anticancer Res. 2019; 39(4):1785-1793. DOI: 10.21873/anticanres.13285. View

12.

Kozielski K, Tzeng S, De Mendoza B, Green J . Bioreducible cationic polymer-based nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain cancer cells. ACS Nano. 2014; 8(4):3232-41. PMC: 4004313. DOI: 10.1021/nn500704t. View

13.

Sasayama Y, Hasegawa M, Taguchi E, Kubota K, Kuboyama T, Naoi T . In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors. J Control Release. 2019; 311-312:245-256. DOI: 10.1016/j.jconrel.2019.09.004. View

14.

Scarabel L, Perrone F, Garziera M, Farra R, Grassi M, Musiani F . Strategies to optimize siRNA delivery to hepatocellular carcinoma cells. Expert Opin Drug Deliv. 2017; 14(6):797-810. DOI: 10.1080/17425247.2017.1292247. View

15.

Jin L, Wang Q, Chen J, Wang Z, Xin H, Zhang D . Efficient Delivery of Therapeutic siRNA by FeO Magnetic Nanoparticles into Oral Cancer Cells. Pharmaceutics. 2019; 11(11). PMC: 6921101. DOI: 10.3390/pharmaceutics11110615. View

16.

Han W, Yuan Y, Li H, Fu Z, Wang M, Guan S . Design and anti-tumor activity of self-loaded nanocarriers of siRNA. Colloids Surf B Biointerfaces. 2019; 183:110385. DOI: 10.1016/j.colsurfb.2019.110385. View

17.

Kulkarni J, Witzigmann D, Chen S, Cullis P, van der Meel R . Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. Acc Chem Res. 2019; 52(9):2435-2444. DOI: 10.1021/acs.accounts.9b00368. View

18.

Diao L, Tao J, Wang Y, Hu Y, He W . Co-Delivery Of Dihydroartemisinin And HMGB1 siRNA By TAT-Modified Cationic Liposomes Through The TLR4 Signaling Pathway For Treatment Of Lupus Nephritis. Int J Nanomedicine. 2019; 14:8627-8645. PMC: 6839745. DOI: 10.2147/IJN.S220754. View

19.

Pezzoli D, Tallarita E, Rosini E, Candiani G . Characterization and Investigation of Redox-Sensitive Liposomes for Gene Delivery. Methods Mol Biol. 2016; 1445:217-33. DOI: 10.1007/978-1-4939-3718-9_14. View

20.

Bhattacharjee S, Roche B, Martienssen R . RNA-induced initiation of transcriptional silencing (RITS) complex structure and function. RNA Biol. 2019; 16(9):1133-1146. PMC: 6693537. DOI: 10.1080/15476286.2019.1621624. View